肝臓疾患におけるイリドオイド: 機械的洞察と分子機構

Shagun Sanjivv Dogra¹, Vikram Patial¹

¹Pharmacology and Toxicology Laboratory, Dietetics & Nutrition Technology Division, CSIR-Institute of Himalayan Bioresource Technology, Palampur 176061, Himachal Pradesh, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad- 201002, India.

Journal of integrative medicine

|February 17, 2026

まとめ

薬用植物からのイリドオイドは,炎症と酸化ストレスを標的として,様々な病気から肝臓を保護する見込みを示しています. 肝臓疾患の治療における臨床応用のためにさらなる研究が必要である.

科学分野:

薬理学薬理学とは
肝臓病理学肝臓病理学
植物化学植物化学

背景:

肝臓疾患は世界的に増加しており,有効な治療法と現在の治療法の副作用は限られている.
薬用植物は,新しい肝臓保護性化合物について調査されています.
薬用植物に見られるイリドオイドは,潜在的な治療効果が認められています.

研究の目的:

イリドオイドの肝臓保護効果に関する科学的研究を全面的に検討する.
肝臓疾患におけるイリドオイドの分子機構と標的経路を解明する.
肝臓疾患の代替治療として,イリドオイドの潜在能力を評価する.

主な方法:

複数の科学データベース (ScienceDirect,Web of Science,PubMed,Wiley Online Library,Scopus) の文献レビューを行った.
イリドオイドと肝臓の健康への影響を調査する研究を含む.
イリドオイドメカニズムに関するインビトロおよびインビボデータの分析.

主要な成果:

イリドオイドは,様々な肝臓疾患に対する肝臓保護効果を顕著に示しています.
主なメカニズムには,炎症,酸化ストレス,アポプトーシス,ミトコンドリア機能障害を標的とする.
証拠によると,イリドオイドは,肝臓疾患の病原化に関与する複数の経路を調節することを示唆しています.

結論:

イリドオイドは,肝臓疾患の管理のための有望な自然化合物のクラスです.
イリドイドの配分を最適化し,ヒトでの臨床試験を実施するために,さらなる研究が不可欠です.
イリドオイドは,肝臓保護における治療的発展のためのさらなる調査を正当化します.

キーワード:

薬物の評価薬物の評価イリドオイド・グリコシド肝臓の病気肝臓の病気肝臓の病気天然製品自然製品です.植物抽出物は植物抽出物です.臨床前試験臨床前試験臨床前試験

さらに関連する動画

09:51

Human Liver Spheroids from Peripheral Blood for Liver Disease Studies

Published on: January 27, 2023

2.3K

05:59

Murine Model of Metastatic Liver Tumors in the Setting of Ischemia Reperfusion Injury

Published on: August 30, 2019

12.6K

関連する概念動画

01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

259

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...

259

01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

212

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...

212

01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

285

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

285

01:14

Hepatic Drug Clearance: Role of Transporters

328

In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...

328

01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

235

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...

235

01:17

Drug Metabolism: Phase I Reactions

5.2K

A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...